KR970005180B1 - Ldl-결합 과산화물에 의해 유발된 맥관성 병변증 예방을 위한 마그네슘-피리독살-5'-포스페이트-글루타민산염을 함유한 약학 조성물 - Google Patents

Ldl-결합 과산화물에 의해 유발된 맥관성 병변증 예방을 위한 마그네슘-피리독살-5'-포스페이트-글루타민산염을 함유한 약학 조성물 Download PDF

Info

Publication number
KR970005180B1
KR970005180B1 KR1019910008233A KR910008233A KR970005180B1 KR 970005180 B1 KR970005180 B1 KR 970005180B1 KR 1019910008233 A KR1019910008233 A KR 1019910008233A KR 910008233 A KR910008233 A KR 910008233A KR 970005180 B1 KR970005180 B1 KR 970005180B1
Authority
KR
South Korea
Prior art keywords
ldl
phosphate
pharmaceutical composition
peroxides
pyridoxal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019910008233A
Other languages
English (en)
Korean (ko)
Other versions
KR910019616A (ko
Inventor
슈나이더 베르너
메이어 브리타
에프.엘스트너 에리히
Original Assignee
슈타이게어발트 아르쯔나이미텔베르크 게엠베하
로브로 엑스 마스셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타이게어발트 아르쯔나이미텔베르크 게엠베하, 로브로 엑스 마스셀 filed Critical 슈타이게어발트 아르쯔나이미텔베르크 게엠베하
Publication of KR910019616A publication Critical patent/KR910019616A/ko
Application granted granted Critical
Publication of KR970005180B1 publication Critical patent/KR970005180B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019910008233A 1990-05-25 1991-05-22 Ldl-결합 과산화물에 의해 유발된 맥관성 병변증 예방을 위한 마그네슘-피리독살-5'-포스페이트-글루타민산염을 함유한 약학 조성물 Expired - Fee Related KR970005180B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4016963A DE4016963A1 (de) 1990-05-25 1990-05-25 Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben
DEP4016963.4 1990-05-25

Publications (2)

Publication Number Publication Date
KR910019616A KR910019616A (ko) 1991-12-19
KR970005180B1 true KR970005180B1 (ko) 1997-04-14

Family

ID=6407228

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008233A Expired - Fee Related KR970005180B1 (ko) 1990-05-25 1991-05-22 Ldl-결합 과산화물에 의해 유발된 맥관성 병변증 예방을 위한 마그네슘-피리독살-5'-포스페이트-글루타민산염을 함유한 약학 조성물

Country Status (28)

Country Link
US (1) US5372999A (enExample)
EP (1) EP0458287B1 (enExample)
JP (1) JPH07119174B2 (enExample)
KR (1) KR970005180B1 (enExample)
CN (1) CN1050750C (enExample)
AT (1) ATE142884T1 (enExample)
AU (1) AU651108B2 (enExample)
CA (1) CA2043228C (enExample)
CZ (1) CZ280683B6 (enExample)
DE (2) DE4016963A1 (enExample)
DK (1) DK0458287T3 (enExample)
EG (1) EG19730A (enExample)
ES (1) ES2091262T3 (enExample)
GR (1) GR3021077T3 (enExample)
HR (1) HRP931445B1 (enExample)
HU (1) HU219223B (enExample)
IE (1) IE76728B1 (enExample)
IL (1) IL98156A (enExample)
IN (1) IN173057B (enExample)
LT (1) LT3335B (enExample)
LV (1) LV10046B (enExample)
MD (1) MD306C2 (enExample)
MX (1) MX171883B (enExample)
RU (1) RU2041713C1 (enExample)
SI (1) SI9110925A (enExample)
SK (1) SK278896B6 (enExample)
UA (1) UA26973A1 (enExample)
ZA (1) ZA913692B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527820A1 (de) * 1995-07-28 1997-01-30 Leniger Follert Elfriede Prof Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem
DE19532625C2 (de) * 1995-09-04 2000-04-20 Steigerwald Arzneimittelwerk Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
AU5840200A (en) 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
AU783855B2 (en) 1999-08-24 2005-12-15 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
WO2001064692A1 (en) 2000-02-29 2001-09-07 Medicure International Inc. Cardioprotective phosphonates and malonates
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
JP2003528146A (ja) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド 脳血管疾患の治療
RU2163132C1 (ru) * 2000-06-01 2001-02-20 Научно-исследовательский центр традиционной фитотерапии Способ лечения сердечно-сосудистых заболеваний фитопрепаратом и лекарственный сбор для лечения сердечно-сосудистых заболеваний
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
DE60128912T9 (de) 2000-07-07 2008-06-26 Medicure International Inc. Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
JP2008517956A (ja) 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド 二重の抗血小板性／抗凝固性ピリドキシン類似体
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
CA2680801A1 (en) 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
RU2484843C1 (ru) * 2012-04-03 2013-06-20 Алексей Кириллович Пехтерев Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246172C (enExample)
DE2461742C2 (de) * 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker

Also Published As

Publication number Publication date
CN1050750C (zh) 2000-03-29
UA26973A1 (uk) 2000-02-28
HU911756D0 (en) 1991-12-30
SK278896B6 (sk) 1998-04-08
US5372999A (en) 1994-12-13
AU7730191A (en) 1991-11-28
MD306C2 (ro) 1996-02-29
RU2041713C1 (ru) 1995-08-20
IN173057B (enExample) 1994-02-05
SI9110925A (sl) 1998-06-30
DE69122170T2 (de) 1997-02-20
EP0458287A2 (en) 1991-11-27
DE4016963C2 (enExample) 1992-04-30
CZ280683B6 (cs) 1996-04-17
EP0458287B1 (en) 1996-09-18
CA2043228A1 (en) 1991-11-26
CS156391A3 (en) 1992-02-19
CA2043228C (en) 1998-07-14
DK0458287T3 (da) 1996-10-07
LV10046B (en) 1995-02-20
IE76728B1 (en) 1997-11-05
ATE142884T1 (de) 1996-10-15
MX171883B (es) 1993-11-22
LT3335B (en) 1995-07-25
HUT58204A (en) 1992-02-28
CN1057391A (zh) 1992-01-01
DE4016963A1 (de) 1991-11-28
LTIP580A (en) 1994-12-27
HRP931445A2 (en) 1996-02-29
LV10046A (lv) 1994-05-10
HRP931445B1 (en) 2000-04-30
HU219223B (en) 2001-03-28
AU651108B2 (en) 1994-07-14
ES2091262T3 (es) 1996-11-01
GR3021077T3 (en) 1996-12-31
DE69122170D1 (de) 1996-10-24
IL98156A0 (en) 1992-06-21
IL98156A (en) 1996-06-18
JPH07119174B2 (ja) 1995-12-20
ZA913692B (en) 1992-02-26
KR910019616A (ko) 1991-12-19
JPH04235130A (ja) 1992-08-24
MD306B1 (ro) 1995-10-31
EG19730A (en) 1996-01-31
IE911783A1 (en) 1991-12-04
EP0458287A3 (en) 1992-04-08

Similar Documents

Publication Publication Date Title
KR970005180B1 (ko) Ldl-결합 과산화물에 의해 유발된 맥관성 병변증 예방을 위한 마그네슘-피리독살-5'-포스페이트-글루타민산염을 함유한 약학 조성물
Stringer et al. Lipid peroxides and atherosclerosis.
Catapano Antioxidant effect of flavonoids
Saynor et al. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n− 3 fatty acids in subjects receiving fish oil supplements and followed for seven years
Salonen et al. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoprotems, and atherosclerotic progression
EP0861070B1 (en) Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis
Leigh-Firbank et al. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses
Kingsbury et al. Abnormal fatty acid composition and human atherosclerosis
Britton et al. Lipid peroxidation and associated hepatic organelle dysfunction in iron overload
Donnelly et al. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients.
McClaskey et al. Subdural hematoma after a fall in an elderly patient taking high‐dose omega‐3 fatty acids with warfarin and aspirin: case report and review of the literature
Moor et al. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age
Stevenson 7 Metabolic effects of the menopause and oestrogen replacement
Grundy Oxidized LDL and atherogenesis: relation to risk factors for coronary heart disease
De Faire et al. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials
Brattström et al. Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate
Hansen et al. Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa).
Dabbagh et al. Effect of iron complexes on adjuvant arthritis in rats.
US20060009486A1 (en) Composition and method for treatment and prevention of coronary artery disease
Das Can free radicals induce coronary vasospasm and acute myocardial infarction?
EP0532706A1 (en) REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS USING ASCORBATE AND LIPOPROTEIN BINDING INHIBITORS (a).
Kostner et al. Low density lipoprotein immunoapheresis does not increase plasma lipid peroxidation products in vivo
Parthasarathy Oxidation of low density lipoprotein (LDL) by cells
Siderova et al. P. 109 Early enrichment of WBC and platelet membranes with ω3 fatty acids (FA) during lipid infusion results from direct FA processing in these cells
Stachowska et al. Possible interactions of fluoride, calcium, and fatty acids in atherosclerotic plaques

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20000806

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20000806